Cutaneous sporotrichosis treatment with potassium iodide: a 24 year experience in São Paulo state, Brazil

Yamada, Karin; Zaitz, Clarisse; Framil, Valéria Maria de Souza; Muramatu, Laura Hitomi

doi:10.1590/s0036-46652011000200006

Cited by 27 publications

(17 citation statements)

References 21 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thyroid stim ulating hormone screening is prudent to ensure that thyroid function remains normal after 1 month of treatment. 25 The dose of SSKI for feline sporotrichosis treatment according to the literature is 20 mg/kg q24h or q12h. 21,24 Nevertheless, the median dose used to achieve cure with KI in capsules in our study was lower (15 mg/kg) than that established in the literature.…”

Section: Discussionmentioning

confidence: 99%

Potassium iodide capsule treatment of feline sporotrichosis

Reis

Gremião

Kitada

et al. 2012

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Sporotrichosis is a mycosis caused by Sporothrix schenckii. The most affected animal is the cat; it has played an important role in the zoonotic transmission of this disease, especially in Rio de Janeiro, Brazil, since 1998. In order to evaluate the treatment of feline sporotrichosis with potassium iodide, an observational cohort was conducted in 48 cats with sporotrichosis at Instituto de Pesquisa Clínica Evandro Chagas, Fiocruz. All cats received potassium iodide capsules, 2.5 mg/kg to 20 mg/kg q24h. The cure rate was 47.9%, treatment failure was 37.5%, treatment abandonment was 10.4% and death was 4.2%. Clinical adverse effects were observed in 52.1% of the cases. Thirteen cats had a mild increase in hepatic transaminase levels during the treatment, six of them presented clinical signs suggestive of hepatotoxicity. Compared to previous studies with itraconazole and iodide in saturated solution, potassium iodide capsules are an alternative for feline sporotrichosis treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Potassium iodide capsule treatment of feline sporotrichosis

Reis

Gremião

Kitada

et al. 2012

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

show abstract

“…The Sporothrix genus, embedded in the plant-associated order Ophiostomatales, exhibits high genetic diversity [10,11], which is accompanied by a diversity of in vitro responses to the main antifungal agents [14] used in sporotrichosis treatment [7,15]. Such agents include potassium iodide [16] and itraconazole [17] for localized cutaneous and lymphocutaneous forms, and amphotericin B for disseminated cases [6,9,16]. Screening for antifungal susceptibilities during epidemiological surveillance programs could help to uncover putative multidrug resistant Sporothrix strains, and improve our ability to adjust therapeutic regimens and reduce relapse.…”

Section: Introductionmentioning

confidence: 99%

Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis

et al. 2014

View full text Add to dashboard Cite

BackgroundSporotrichosis is a chronic subcutaneous mycosis of humans and animals, which is typically acquired by traumatic inoculation of plant material contaminated with Sporothrix propagules, or via animals, mainly felines. Sporothrix infections notably occur in outbreaks, with large epidemics currently taking place in southeastern Brazil and northeastern China. Pathogenic species include Sporothrix brasiliensis, Sporothrix schenckii s. str., Sporothrix globosa, and Sporothrix luriei, which exhibit differing geographical distribution, virulence, and resistance to antifungals. The phylogenetically remote species Sporothrix mexicana also shows a mild pathogenic potential.MethodsWe assessed a genetically diverse panel of 68 strains. Susceptibility profiles of medically important Sporothrix species were evaluated by measuring the MICs and MFCs for amphotericin B (AMB), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), posaconazole (PCZ), flucytosine (5FC), and caspofungin (CAS). Haplotype networks were constructed to reveal interspecific divergences within clinical Sporothrix species to evaluate genetically deviant isolates.ResultsITC and PCZ were moderately effective against S. brasiliensis (MIC90 = 2 and 2 μg/mL, respectively) and S. schenckii (MIC90 = 4 and 2 μg/mL, respectively). PCZ also showed low MICs against the rare species S. mexicana. 5FC, CAS, and FLC showed no antifungal activity against any Sporothrix species. The minimum fungicidal concentration ranged from 2 to >16 μg/mL for AMB against S. brasiliensis and S. schenckii, while the MFC90 was >16 μg/mL for ITC, VRC, and PCZ.ConclusionSporothrix species in general showed high degrees of resistance against antifungals. Evaluating a genetically diverse panel of strains revealed evidence of multidrug resistant phenotypes, underlining the need for molecular identification of etiologic agents to predict therapeutic outcome.

show abstract

“…Potassium iodide, especially in endemic areas of developing countries, has been described as a more affordable and equally effective option in cutaneous forms, allowing imidazole derivatives to be used as first option or alternative drug for the treatment of localized cases. 9 , 10 In disseminated cases or in patients with AIDS, amphotericin B is the drug of choice. 3 Non-pharmacological therapeutic approaches, based on the application of thermotherapy by different methods have been described with varying success rates.…”

mentioning

confidence: 99%

Characterization of sporotrichosis cases treated in a dermatologic teaching unit in the state of São Paulo - Brazil, 2003 - 2013

Marques

Martins

Sousa

et al. 2015

An. Bras. Dermatol.

View full text Add to dashboard Cite

We conducted a transversal retrospective study with secondary data collection from 25 cases of sporotrichosis, treated at a teaching unit in inner São Paulo (Brazil), between the years 2003-2013. We found that the prevalence was higher in men (72%), rural workers (44%) and those living in rural areas (60%), with an average age of 42.48 years. The median between the onset of lesions and diagnosis was six weeks. Lesions predominated in the upper limbs (92%), and were classified as lymphocutaneous (80%) and fixed cutaneous (20%) forms. Clinical cure was observed in 62.5% of the cases treated with potassium iodide and 100% of cases treated with itraconazole.

show abstract

Cutaneous sporotrichosis treatment with potassium iodide: a 24 year experience in São Paulo state, Brazil

Cited by 27 publications

References 21 publications

Potassium iodide capsule treatment of feline sporotrichosis

Potassium iodide capsule treatment of feline sporotrichosis

Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis

Characterization of sporotrichosis cases treated in a dermatologic teaching unit in the state of São Paulo - Brazil, 2003 - 2013

Contact Info

Product

Resources

About